Seminars in Oncology
Volume 29, Issue 6 , Pages 552-562 , December 2002

Use of the best case series to evaluate complementary and alternative therapies for cancer: A systematic review

References 

  1. Bailar JC, Gornik HL. Cancer undefeated. N Engl J Med. 1997;336:1569–1574
  2. Ragnhammar P, Hafstrom L, Nygren P, et al.  Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001;40:282–308
  3. Adams VR. Adverse events associated with chemotherapy for common cancers. Pharmacotherapy. 2000;20:96S–103S
  4. Jansman FG, Sleijfer DT, de Graaf JC, et al.  Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Safety. 2001;24:353–367
  5. Richardson MA, Straus SE. Complementary and alternative medicine: Opportunities and challenges for cancer management and research. Semin Oncol. 2003;30:531–545
  6. House of Representatives Subcommittee on Health and Long-term Care of the Select Committee on Aging . Quackery: A $10 Billion Scandal, 98th Congress, 2nd session. Committee Publication In: 1994;p. 98–435
  7. Byar DP, Simon RM, Friedewald WT, et al.  Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med. 1976;295:74–80
  8. Chalmers I. Evaluating the effects of care during pregnancy and childbirth. In:  Chalmers I,  Enkin M,  Keirse MJNC editor. Effective Care in Pregnancy and Childbirth. New York, NY: Oxford University Press; 1989;p. 4–38
  9. Hulley SB, Cummings SR. Designing Clinical Research. Baltimore, MD: Williams & Wilkins; 1988;
  10. Sackett DL. Rules of evidence and clinical recommendations for the management of patients. Can J Cardiol. 1993;9:487–489
  11. National Institutes of Health . Office of Extramural Research: Award Trends. http://grants.nih.gov/grants/award/awardtr.htm2002;
  12. DiMasi JA. New drug development in the United States from 1963-1999. Clin Pharm Ther. 2001;69:288–296
  13. DiMasi JA. Risks in new drug development: Approval success rates for investigational rugs. Clin Pharm Ther. 2001;69:297–307
  14. PhARMA . Pharmaceutical Industry Profile. http://www.phrma.org/publications/2000;
  15. Office of Technology Assessment: Unconventional Cancer Treatments, OTA-H-405. Washington, DC: US Government Printing Office; 1990;
  16. National Cancer Institute . Office of Cancer Complementary and Alternative Medicine Best Case Series Guidelines. http://www.cancer.gov/occam/2002;
  17. Jenicek M. Clinical Case Reporting in Evidence-Based Medicine. Oxford, UK: Butterworth-Heinemann; 1999;
  18. In:  Berman BM,  Larson DB editor. Alternative Medicine: Expanding Medical Horizons. Bethesda, MD: NIH; 1994; NIH Publication # 94-066
  19. Moss RW. The Cancer Industry—Unraveling the Politics. New York, NY: Paragon House; 1989;
  20. Moss RW. Cancer Therapy: The Independent Consumer's Guide to Non-toxic Treatment and Prevention. New York, NY: Equinox Press; 1994;
  21. Gonzalez N. One Man Alone: An Investigation of Nutrition, Cancer, and William Donald Kelley: Unpublished book, 1987, cited in Office of Technology Assessment. Unconventional Cancer Treatments, OTA-H-405. Washington, DC: US Government Printing Office; 1990;
  22. Vanchieri C. Alternative therapies getting notice through best case series program. J Natl Cancer Inst. 2000;92:1558–1560
  23. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma. Nutr Cancer. 1999;33:115–116
  24. Reed A, James N, Sikora K. Juices, coffee enemas, and cancer. Lancet. 1990;336:677–678
  25. Buckner JC, Malkin MG, Reed E, et al.  Phase II study of Antineoplastons A10 (NSC 648539). Mayo Clin Proc. 1999;74:137–145
  26. Burzynski SR. Efficacy of Antineoplastons A10 and AS2-1. Mayo Clin Proc. 1999;74:641–642
  27. Tsuda H, Sata M, Kumabe T, et al.  Quick response of advanced cancer to chemoradiation therapy with Antineoplastons. Oncol Rep. 1998;5:597–600
  28. Tsuda H, Sata M, Ijuuin H, et al.  A novel strategy for remission induction and maintenance in cancer therapy. Oncol Rep. 2002;9:65–68
  29. Cancer Advisory Panel for Complementary and Alternative Medicine . Meeting Minutes. http://nccam.nih.gov/about/advisory/capcam/minutes/index.htm1999-2002;
  30. Buiatti E, Arniani S, Verdecchia A, et al.  Results from a historical survey of the survival of cancer patients given Di Bella multitherapy. Cancer. 1999;86:2143–2149
  31. Gerson M. A Cancer Therapy. Results of Fifty Cases. ed 3. Del Mar, CA: Totality Book; 1977;
  32. Mather JM, Carrothers AWR, Harlow N, et al.  Report of a committee of faculty members of the University of British Columbia Concerning the Hoxsey Treatment for Cancer. Vancouver, Canada, University of. British Columbia, 1957, as cited in Office of Technology Assessment. Unconventional Cancer Treatments, OTA-H-405. Washington, DC: US Government Printing Office; 1990;
  33. Gold J. Use of hydrazine sulfate in terminal and preterminal cancer patients: Results of investigational new drug study in 84 evaluable patients. Oncology. 1975;32:1–10
  34. Loprinzi CL, Kuross SA, O'Fallon JR, et al.  Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol. 1994;12:1121–1125
  35. Loprinzi CL, Goldberg RM, Su JQ, et al.  Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994;12:1107–1108
  36. Clement RH, Burton L, Lampe GN. Peritoneal mesothelioma. Quantum Med. 1988;1:68–73
  37. Moertel CG, Fleming TR, Rubin J, et al.  A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med. 1982;306:201–206
  38. Monfort H. A new homeopathic approach to neoplastic diseases: From cell destruction to carcinogen-induced apoptosis. Br Homoepathic J. 2000;89:78–83
  39. Ellison NM, Byar DP, Newell GR. Special report on laetrile: The NCI laetrile review. N Engl J Med. 1978;299:549–552
  40. Livingston-Wheeler V, Addeo ED. The Conquest of Cancer: Vaccines and Diet. New York, NY: Franklin Watts; 1984;
  41. Carter JP, Saxe GP, Newbold V, et al.  Hypothesis: Dietary management may improve survival from nutritionally linked cancers based on analysis of representative cases. J Am Coll Nutr. 1993;12:209–226
  42. de la Taille A, Hayek OR, Burchardt M, et al.  Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: Two case reports. J Altern Complement Med. 2000;6:449–451
  43. Lyall D, Schwartz M, Herter FP, et al.  Treatment of cancer by the method of Revici. JAMA. 1965;194:279–280
  44. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chemicobiological Interact. 1974;9:285–315
  45. Creagan ET, Moertel CG, O'Fallon JR, et al.  Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979;301:687–690
  46. Moertel CG, Fleming TR, Creagan ET, et al.  High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985;312:137–141
  47. Hennekens CH, Buring JF. Epidemiology in Medicine. Boston, MA: Little Brown; 1987;
  48. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials. ed 2. Baltimore, MD: Williams & Wilkins; 1988;
  49. Office of Alternative Medicine . Minutes of the Alternative Medicine Program Advisory Committee. Sept 1997;
  50. Hildenbrand GL, Hildenbrand LC, Bradford K, et al.  Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: A retrospective review. Altern Ther Health Med. 1995;1:29–37
  51. Hildenbrand GL, Hildenbrand LC, Bradford K, et al.  The role of follow-up and retrospective data analysis in alternative cancer management: The Gerson experience. J Naturopath Med. 1996;6:49–56
  52. Richardson MA, Russell NC, Sanders T, et al.  Assessment of outcomes at alternative medicine cancer clinics: A feasibility study. J Altern Complement Med. 2001;7:19–32
  53. Shekelle PG, Coulter I, Hurwitz EL, et al.  Congruence between decisions to initiate chiropractic spinal manipulation for low back pain and appropriateness criteria in North America. Ann Intern Med. 1998;129:9–17
  54. Hoffman JR. Rethinking case reports. West J Med. 1999;170:253–254
  55. Stalker DF. Evidence and alternative medicine. Mt Sinai J Med. 1995;62:132–143
  56. Vandenbroucke JP. Case reports in an evidence-based world. J R Soc Med. 1999;92:159–163
  57. Tubert P, Begaud B, Pere J-C, et al.  Power and weakness of spontaneous reporting: A probabilistic approach. J Clin Epidemiol. 1992;45:283–286
  58. Hawkins MJ, Friedman MA:. National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst. 1992;84:1699–1702
  59. Simon R. How large should a phase II trial of a new drug be. Cancer Treat Rep. 1987;71:1079–1085
  60. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134:330–334
  61. National Center for Complementary and Alternative Medicine . Cancer Advisory Panel for Complementary and Alternative Medicine Charter. http://nccam.nih.gov/about/advisory/capcam/2002;

☆ Address reprint requests to Richard L. Nahin, PhD, MPH, 9000 Rockville Pike, Bldg 31, Room 2B11, Bethesda, MD 20892-2182.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0093-7754(02)50318-3

doi: 10.1053/sonc.2002.50004

Seminars in Oncology
Volume 29, Issue 6 , Pages 552-562 , December 2002

Article Tools